Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Artificial Intelligence-Generated Draft Replies to Patient Inbox Messages.
Garcia P, Ma SP, Shah S, Smith M, Jeong Y, Devon-Sand A, Tai-Seale M, Takazawa K, Clutter D, Vogt K, Lugtu C, Rojo M, Lin S, Shanafelt T, Pfeffer MA, Sharp C. Garcia P, et al. Among authors: takazawa k. JAMA Netw Open. 2024 Mar 4;7(3):e243201. doi: 10.1001/jamanetworkopen.2024.3201. JAMA Netw Open. 2024. PMID: 38506805 Free PMC article.
Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
F Schwarz T, Hwang SJ, Ylisastigui P, Liu CS, Takazawa K, Yono M, Ervin JE, Andrews CP, Fogarty C, Eckermann T, Collete D, de Heusch M, De Schrevel N, Salaun B, Lambert A, Maréchal C, Olivier A, Nakanwagi P, Lievens M, Hulstrøm V. F Schwarz T, et al. Among authors: takazawa k. J Infect Dis. 2023 Dec 14:jiad546. doi: 10.1093/infdis/jiad546. Online ahead of print. J Infect Dis. 2023. PMID: 38099559
Long Term Follow-Up Study of a Randomized, Open-Label, Uncontrolled, Phase I/II Study to Assess the Safety and Immunogenicity of Intramuscular and Intradermal Doses of COVID-19 DNA Vaccine (AG0302-COVID19).
Nakagami H, Matsumoto T, Takazawa K, Sekino H, Matsuoka O, Inoue S, Furuie H, Morishita R. Nakagami H, et al. Among authors: takazawa k. Vaccines (Basel). 2023 Sep 28;11(10):1535. doi: 10.3390/vaccines11101535. Vaccines (Basel). 2023. PMID: 37896939 Free PMC article.
DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study.
Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, Sogawa Y, Kumazaki M, Jonai N, Matsunaga S, Takeshita F, Yoshihara K, Ishizuka H. Toyama K, et al. Among authors: takazawa k. Vaccine. 2023 Aug 31;41(38):5525-5534. doi: 10.1016/j.vaccine.2023.07.012. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586958 Free article. Clinical Trial.
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.
Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V; AReSVi-006 Study Group. Papi A, et al. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. N Engl J Med. 2023. PMID: 36791160 Clinical Trial.
221 results